Skip Ribbon Commands
Skip to main content
Menu
Prof Pierce Chow

Prof Chow Kah Hoe Pierce

MBBS (NUS), M.Med (Surg), FRCS (Edinburgh), FAMS (Gen Surg), PhD (NUS)

Senior Consultant

National Cancer Centre Singapore

Specialty: Surgery & Surgical Oncology

Sub-specialties: Hepato-pancreato-biliary and Transplant Surgery, General Surgery, Hepato-Pancreato-Biliary, Liver

Conditions Treated by this Doctor:
Bile Duct Cancer, Biliary Tract Cancer, Liver Cancer, Pancreatic Cancer, Pancreatico-Biliary Diseases.

Clinical Appointments

  • Senior Consultant Division of Surgery & Surgical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Senior Consultant Hepato-pancreato-biliary and Transplant Surgery Singapore General HospitalSingapore General Hospital

Academic Appointments

  • Professor and Program Director, PhD Programme in Clinical Sciences, Duke-NUS Medical School
  • Academic Vice Chair (Research), Academic Clinical Programme for Surgery (SURG ACP)

Profile

Pierce Chow is Professor and Program Director at the Duke-NUS Medical School and Senior Consultant Surgeon at the National Cancer Centre Singapore and the Singapore General Hospital. He is concurrently a National Medical Research Council (NMRC) funded Senior Clinician-Scientist and founding President of the College of Clinician Scientists, Academy of Medicine Singapore.

In addition to managing a busy HPB surgical oncology service, Prof Chow has researched extensively on hepatocellular carcinoma (HCC). He is the Protocol Chair of the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group and leads multi-national investigator-initiated clinical studies. Prof Chow currently leads the multi-disciplinary NMRC TCR National Flagship Program in Liver Cancer (the PLANet study) and the ASTAR funded IAF-ICP nation-wide cohort study to develop diagnostics for early detection of hepatocellular carcinoma in high-risk patients (the ELEGANCE study). For his dedicated research on liver cancer, Pierce was conferred the NMRC National Outstanding Clinician Scientist Award in 2012.

Pierce is also a faculty member at the Genome Institute of Singapore and the SingHealth Duke-NUS Global Health Institute and Research Director at the Institute of Cell and Molecular Biology Singapore.

Education

  • PhD, National University of Singapore, 2004
  • Fellowship Diploma, Academy of Medicine, Singapore, 1999
  • Fellowship Diploma (FRCS), Royal College of Surgeons, Edinburgh, 1994
  • M.Med (Surgery), National University of Singapore, 1994
  • MBBS, National University of Singapore, 1989

Professional Appointments and Committee Memberships

  • Co-Chair, Research and Scholarship Committee, Duke-NUS Medical School
  • Member, Research Committee, Specialists Accreditation Board, Ministry of Health
  • Faculty Member, SingHealth Duke-NUS Global Health Institute (SDGHI), Duke-NUS Medical School
  • Local Review Panel Member, NMRC Clinician Scientist – Individual Research Grant (CS-IRG) Scheme
  • Chairman, Academic Medicine Grant Review Committee – Clinical Research (AGRC-Clinical), SingHealth
  • Member, National Advisory Committee for Laboratory Animal Research (NACLAR), National Research Foundation
  • Member, Novel Agents Committee for Cancer (NACC), A*STAR
  • Member, Faculty of Medical Experts (FME), Academy of Medicine
  • Member, Advisory Committee, SingHealth Experimental Medicine Centre (SEMC)
  • Founding President, College of Clinician Scientists, Academy of Medicine Singapore
  • Research Director, Institute of Molecular Cell Biology (IMCB)
  • Director, Academy of Medicine Singapore
  • Associate Faculty, Senior Group Leader, Genome Institute of Singapore (GIS)
  • Member, Research Committee, Specialists Accreditation Board, Ministry of Health
  • Member, SAB Research Committee Research Training Review Panel, Specialists Accreditation Board, Ministry of Health
  • Member, Asia-Pacific Hepato-Pancreato-Biliary Association
  • Member, International Hepato-Pancreato-Biliary Association
  • Member, International Liver Cancer Association
  • Member, Australasian Gastrointestinal Trials Group
  • Member, Singapore Society of Oncology
  • Protocol Chair, Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group
  • Fellow, The Royal College of Surgeons of Edinburgh (RCSEd)
  • Fellow, Singapore Medical Association

Awards

  • Singapore Health Quality Service Awards, Silver Award, 2020
  • Senior Investigator Clinician Scientist Award, National Medical Research Council, 2018
  • Honorary Fellow, Academy of Medicine Malaysia, 2017
  • Honorary Fellow, Hepatology Society of the Philippines, 2016
  • National Day Awards, Pingkat Bakti Setia, Government of Singapore, 2016
  • NMRC Translational and Clinical Research Flagship Program Award, 2016
  • SingHealth Duke-NUS Research Team Award, 2nd Prize, 2015
  • Outstanding Faculty for Engagement Award (Normal Body), Duke-NUS, 2013
  • Outstanding Faculty for Engagement Award (Surgery), Duke-NUS, 2012
  • Outstanding Faculty for Advocacy Award (Normal Body), Duke-NUS, 2012
  • National Outstanding Clinician Scientist Award, National Medical Research Council, 2012
  • Pioneer Award, Duke-NUS Graduate Medical School, 2011
  • Singapore Health Quality Service Award, Silver, 2011
  • Outstanding Educator Award, Duke-NUS Graduate Medical School, 2010
  • Senior Investigator Clinician Scientist Award, National Medical Research Council, 2010
  • Service With A Heart Award, Singapore General Hospital, 2010
  • Outstanding Educator Award, Duke-NUS Graduate Medical School, 2009
  • Excellent Publication Award, SingHealth (Singapore General Hospital), 2006
  • Excellent Service Award (Gold), Healthcare. Spring Singapore, 2004
  • SARS Courage Medal, Government of Singapore, 2003
  • Sir James Fraser Fellow, Royal College of Surgeons of Edinburgh, 2002
  • HMDP Clinical Fellowship in HPB Surgery and Liver Transplantation, 1999
  • NMRC - Singapore Totalisator Board Medical Research Fellowship, 1997
  • Seah Cheng Siang Prize GE Society of Singapore, Best original research, 1997
  • NMRC - Kwek Hong Png Medical Research Fellowship, 1995
  • Young Surgeon's Award Academy of Medicine, Singapore. Best original research, 1995
  • Chapter of Surgeon's Gold Medal Conjoint M.Med (Surgery)/FRCS (Edin) Exam, 1994

Research Interests

  • Genomics, immunomics, metabolomics as applied to Precision Medicine in Hepatocellular Carcinoma
  • Clinical Trials and Translational Research in hepatocellular carcinoma, pancreatic carcinoma, gastro-intestinal stromal tumour and surgical oncology
  • Meta-analysis, systemic review and health services outcomes research in Hepatocellular Carcinoma
  • Brachytherapy and Selective Internal Radiation Therapy
  • Clinical and Pre-clinical molecular and functional imaging. Non-human primate models. Patient tumour-explant xenografts and orthotopic models in experimental oncology.

Publications

Selected Publications of the past 5 years

  • Zhai WW, Lai H, Kaya NA, Chen J, Yang HC, Lu BX, …, Tam WL, Toh HC, Foo RSY, Chow PKH. (2021) Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in Hepatocellular Carcinoma: the PLANET study, Nat. Sci. Rev. https://doi.org/10.1093/nsr/nwab192
  • Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. (2021) Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer. https://doi.org/10.1159/000514400
  • Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M, Lai L, Tam WL, Lim TKH, Wan WK, Loh T, Leow WQ, Pang YH, Chan CY, Lee SY, Cheow PC, Toh HC, Ginhoux F, Iyer S, Kow AWC, Young Dan Y, Chung A, Goh BKP, Albani S, Chow PKH, Zhai W, Chew V. (2021) Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat Commun., 12(1):227. https://doi.org/10.1038/s41467-020-20171-7. PMID: 33431814.
  • Gandhi M, Ling WH, Chen CH, Lee JH, Kudo M, Chanwat R, Strasser SI, Xu Z, Lai SH, Chow PKH. (2021) Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study. J Hepatocell Carcinoma, 8:1159-67. https://doi.org/10.2147/JHC.S329018
  • Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. (2021) APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol. Int., 1-18. https://doi.org/ 10.1007/s12072-021-10239-x
  • Mulder K, Patel AA, Kong WT, Piot C, Halitzki E, Dunsmore G, Kalilnezhad S, Irac SE, Dubuisson A, Chevrier M, Zhang XM, Tan JKC, Lim TKH, Wong RMM, Pai R, Khalil AIS, Chow PKH, Wu SZ, … Ginhoux F. (2021) Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity, 54:1-8. https://doi.org/10.1016/j.immuni.2021.07.007
  • Hack, S. P., Spahn, J., Chen, M., Cheng, A. L., Kaseb, A., Kudo, M., Lee, H. C., Yopp, A., Chow, P., & Qin, S. (2020). IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol., 16(15):975–89. https://doi.org/10.2217/fon-2020-0162
  • Sharma A, Seow JJW, Dutertre CA, Pai R, Blériot C, Mishra A, Wong RMM, Singh GSN, Sudhagar S, Khalilnezhad S, Erdal S, Teo HM, Khalilnezhad A, Chakarov S, Lim TKH, Fui ACY, Chieh AKW, Chung CP, Bonney GK, Goh BK, Chan JKY, Chow PKH, Ginhoux F, DasGupta R. (2020) Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell, 183(2):377-394.e21. https://doi.org/10.1016/j.cell.2020.08.040. PMID: 32976798
  • Ding, Z., Ericksen, R, Escande-Beillard, N., Lee, Q.Y, Loh A., Denil, S., Steckel, M., Andrea Haegebarth, A., Ho, S.W., Chow, P.K., Toh, H.C., Reversade, B., Gruenewald, S., Han, W. (2020) Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J. Hepatol., 72(4):725-35, ISSN 0168-8278, https://doi.org/10.1016/j.jhep.2019.10.026
  • Chow PKH, Mihir Gandhi, Say-Beng Tan, et al. (2018) SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J. Clin. Oncol., JCO2017760892. https://doi.org/10.1200/JCO.2017.76.0892.
  • Chew, V., Lee, Y.H., Pan, L., Nasir, N.J.M., Lim, C.J., Chua, C., Lai, L., Hazirah, S.N., Lim, T.K.H., Goh, B.K.P., Chung, A., Lo, R.H.G., Ng, D., Filarca, R.L.F, Albani, S., and Chow, P.K.H. (2018). Immune Activation Underlies a Sustained Clinical Response to Yttrium-90 Radioembolisation in Hepatocellular Carcinoma. Gut. pii: gutjnl-2017-315485. https://doi.org/10.1136/gutjnl-2017-315485.
  • Zhao, Y., Shuen, T.W.H., Toh, T.B., Chan, X.Y., Liu, M., Tan, S.Y., Fan, Y., Yang, H., Lyer, S.G., Bonney, G.K., Loh, E., Chang, K.T.E., Tan, T.C., Zhai, W., Chan, J.K.Y., Chow, E.K., Chee, C.E., Lee, G.H., Dan, Y.Y., Chow, P.K., Toh, H.C., Lim, S.G., and Chen, Q. (2018). Development of a New Patient-Derived Xenograft Humanised Mouse Model to Study Human-Specific Tumour Microenvironment and Immunotherapy. Gut. pii: gutjnl-2017-315201. https://doi.org/10.1136/gutjnl-2017-315201.
  • Lim, C.J., Lee, Y.H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T.K.H., Yeong, J., Toh, H.C., Lee, S.Y., Chan, C.Y., Goh, B.K., Chung, A., Heikenwalder, M., Ng, I.O., Chow, P., Albani, S., and Chew, V. (2018). Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut. https://doi.org/10.1136/gutjnl-2018-316510.
  • Zhai W, Lim TK, Zhang T, Phang ST, Tiang Z, Guan P, Ng MH, Lim JQ, Yao F, Li Z, Ng PY, Yan J, Goh BK, Chung AY, Choo SP, Khor CC, Soon WW, Sung KW, Foo RS, Chow PK (2017) The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun. 8:4565. https://doi.org/10.1038/ncomms14565
  • Pardo, F., Sangro, B., Lee, R.C., Manas, D., Jeyarajah, R., Donckier, V., Maleux, G., Pinna, A.D., Bester, L., Morris, D.L., Iannitti, D., Chow, P.K., Stubbs, R., Gow, P.J., Masi, G., Fisher, K.T., Lau, W.Y., Kouladouros, K., Katsanos, G., Ercolani, G., Rotellar, F., Bilbao, J.I., and Schoen, M. (2017). The Post-Sir-Spheres Surgery Study (P4s) Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. Ann. Surg. Oncol. 24(9):2465-73. https://doi.org/10.1245/s10434-017-5950-z.

Research Trials

  • Development of a companion diagnostic test kit for selective internal radiation therapy and immunotherapy for hepatocellular carcinoma (HCC): A prospective clinical translational study
  • Prospective Cohort Study of Changes in Circulatory MicroRNA after Surgical Resection of Hepatocellular Carcinoma
    https://clinicaltrials.gov/ct2/show/NCT05148572 (AHCC11 PROSECT)
  • Early detection of hepatocellular carcinoma (HCC): miRNA, microbiome and imaging biomarkers in the evolution of chronic liver disease in a high-risk prospective cohort
    https://clinicaltrials.gov/ct2/show/NCT04965259 (AHCC10 ELEGANCE)
  • Decoding global gene expression in liver cancer through deep learning and standard-of-care clinical imaging
  • A Patient-Specific Diagnostic and Predictive Platform for Precision Medicine in HCC
  • Hepatocellular Carcinoma (HCC) Registry in Asia
    http://clinicaltrials.gov/ct2/show/NCT03233360 (AHCC08)
  • A Prospective Study to develop a Genomics-Immunomics- Phenomics Platform for Precision Medicine in HCC
  • Comprehensive interrogation of the epigenetics promoter and enhancer landscape in HCC to identify aberrant regulatory mechanisms associated with HCC
  • The use of LiverMultiScan ("LMS") to analyse HCC patients' MRI scans for improved monitoring of patients' prognosis and selection of therapy
  • Post-SIR Spheres® surgery study (P4S): a retrospective analysis in patients with primary liver tumours or secondary hepatic metastases
  • Artificial Liver Platform for Next-Generation Drug Discovery and Development
  • Precision Medicine in Liver Cancer across an Asia-Pacific Network
    http://clinicaltrials.gov/ct2/show/NCT03267641 (AHCC07 PLANET)
  • Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma
    http://clinicaltrials.gov/ct2/show/NCT01135056 (AHCC06 SIRveNIB)
  • Effect of YQ23 on Radiation sensitization in a Hepatoma Model
  • Study of SIR-Spheres plus Sorafenib as 1st Line Treatment for Non-Resectable Primary Hepatocellular Carcinoma
    http://clinicaltrials.gov/ct2/show/NCT00712790 (AHCC05)
  • A Study of the Safety Profile of Three Escalating Radioactivity Levels of 32P BioSilicon Delivered with the SIMPL Needle as Intratumoural Implantations in Patients With Unresectable Hepatocellular Carcinoma
    https://clinicaltrials.gov/ct2/show/NCT00247260 (AHCC04)   
  • Randomized Phase III Trial to determine the Effectiveness of Megestrol Acetate in treating Patients who have Liver Cancer that cannot be removed by surgery
    http://www.clinicaltrials.gov/ct/gui/show/NCT00041275 (AHCC02)
  • Phase III Randomized Study of High Dose Tamoxifen versus Placebo in Patients with Inoperable Hepatocellular Carcinoma
    http://clinicaltrials.gov/ct/show/NCT00003424 (AHCC01)